Jubilant Life’s arm gets TGA’s nod for Lyophilized kit for the preparation of Technetium MAA

Jubilant Life Sciences’ wholly own subsidiary Jubilant Pharma, through one of its units Jubilant DraxImage Inc. Montreal Canada (JDI), has received approval from TGA, Australia for Lyophilized kit for the preparation of Technetium 99m Macro-Aggregated Albumin (MAA) Injection.

MAA provides accurate scans to assess lung perfusion and rule out pulmonary embolism with low radiation exposure. JDI is the leading supplier of MAA in the US and has approval in four other countries including Canada, Columbia, Hong Kong and Israel. The Australian MAA product is expected to be launched as part of JDI’s larger commitment to investing in the growth and robust sustainability of Nuclear Medicine globally and cater to the needs of suspected pulmonary embolism patients.

Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.